Company Overview - Halozyme Therapeutics, Inc. is a biopharmaceutical company focused on advancing disruptive solutions to enhance patient experiences and outcomes for both emerging and established therapies [3] - The company is known for its ENHANZE® drug delivery technology, which utilizes the proprietary enzyme rHuPH20 to facilitate subcutaneous delivery of injected drugs and fluids, aiming to improve patient experience through rapid delivery and reduced treatment burden [3] - Halozyme has impacted one million patient lives through post-marketing use of ten commercialized products across more than 100 global markets [3] Product and Technology - Halozyme has licensed its ENHANZE® technology to major pharmaceutical and biotechnology companies, including Roche, Takeda, Pfizer, and AbbVie, among others [3] - The company also develops and commercializes drug-device combination products using advanced auto-injector technologies, which offer advantages such as improved convenience, reliability, and patient comfort [4] - Halozyme has two proprietary commercial products, Hylenex® and XYOSTED®, and is engaged in ongoing product development programs with partners like Teva Pharmaceuticals and McDermott Laboratories Limited [4] Upcoming Events - Dr. Helen Torley, the president and CEO of Halozyme, will present and host investor meetings at the BofA Securities 2025 Healthcare Conference on May 13, 2025, at 4:20 PM PT / 7:20 PM ET [1] - A live audio webcast of the presentation will be available on the company's Investor Relations website, with replays accessible for 90 days post-conference [2]

Core Insights - Halozyme Therapeutics, Inc. announced that argenx received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending European Commission (EC) approval of VYVGART® 1000mg for treating chronic inflammatory demyelinating polyneuropathy (CIDP) [1][4] - VYVGART® is the first targeted IgG Fc-antibody fragment for CIDP and represents the first novel mechanism of action for CIDP treatment in over 30 years [2] - The CHMP recommendation is based on positive results from the ADHERE clinical trial, the largest study of CIDP patients to date [4] Company Overview - Halozyme is a biopharmaceutical company focused on improving patient experiences and outcomes through its ENHANZE® drug delivery technology, which facilitates subcutaneous delivery of injected drugs [5] - The company has licensed its ENHANZE® technology to major pharmaceutical companies including Roche, Takeda, and Pfizer, impacting over one million patients globally [5] - Halozyme also develops drug-device combination products aimed at enhancing patient comfort and adherence [6] Market Implications - The EC decision on the marketing authorization application is expected within approximately two months, which will apply to all 27 EU Member States and additional countries [1][4] - The approval of VYVGART® could provide a groundbreaking treatment option for patients with rare autoimmune diseases across Europe [3]

Table of Contents As filed with the U.S. Securities and Exchange Commission on December 15, 2023. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 TRISALUS LIFE SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 3841 (Primary Standard Industrial Classification Code Number) 85-3009869 (I.R.S. Employer Identific ...